Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00246857 · ClinicalTrials.gov registry record
Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
A clinical trial of Primary Immune Deficiency, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- 5,000
- Enrollment target
- 7
- Study locations
NCT00246857 is a study of Primary Immune Deficiency that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 5,000 participants, above the 205-participant average among 5 other Primary Immune Deficiency trials with a reported enrollment target (2339% higher). The trial reports 7 study locations across 3 states.
The verdict
NCT00246857, a study of Primary Immune Deficiency, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study will determine the biochemical and genetic causes of inherited immune diseases affecting lymphocyte homeostasis. Lymphocytes are a type of white blood cell that fights infections. Normally, the body keeps a precise balance in which lymphocyte growth is matched by lymphocyte death. People with constantly enlarged lymph nodes or spleen, along with autoimmune disease, immunodeficiency, lymphoma, or other immune problems affecting lymphocytes may have an abnormality of the immune system in the cell growth and cell death processes that regulate lymphocyte homeostasis. Patients who have, or are suspected of having, an inherited lymphocyte homeostasis or programmed cell death susceptibility syndrome may be eligible for this study. Relatives of patients are also included. Participants' (patients and relatives) medical records are reviewed and blood samples are drawn for studies to identify genes involved in immune disorders. Tissues that have been removed from patients for medical reasons, such as biopsied tissues, may be examined for tissue and DNA studies. Relatives are studied to determine if some of them may have a very mild form of lymphocyte homeostasis disorder. Patients who have an immune problem that the researchers wish to study further will be invited to donate additional blood samples at irregular intervals (at least once a year) and to provide an update of their medical records at the same time.
Conditions Studied
Study Locations (7)
Other
- Ankara Medical University - Ankara
- Gazi University - Ankara
- Hacettepe University - Ankara
- Marmara University - Istanbul
- Necemttin Erbakan University - Konya
Maryland
- National Institutes of Health Clinical Center - Bethesda
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2007-02-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00246857
The ClinicalTrials.gov registry entry for NCT00246857 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 205-participant average among 5 other Primary Immune Deficiency trials with a reported enrollment target (2339% higher). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Immune Deficiency appearing as the primary indexed condition, and to 0 interventions.
NCT00246857 reports 7 study locations spanning 3 distinct geographic areas - top geographies include Other, Maryland, Michigan.
Frequently Asked Questions
What is clinical trial NCT00246857 about?
NCT00246857 is a clinical study titled "Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death". This study will determine the biochemical and genetic causes of inherited immune diseases affecting lymphocyte homeostasis. Lymphocytes are a type of white blood cell that fights infections. Normally, the body keeps a precise balance in which lymphocyte growth is matched by lymphocyte death. People ...
What is the current status of trial NCT00246857?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2007-02-12.
What conditions does trial NCT00246857 study?
This clinical trial studies the following conditions: Primary Immune Deficiency.
Who is sponsoring clinical trial NCT00246857?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00246857 being conducted?
This trial has 7 study locations across Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Immune Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Biologics And Clinical Immunology Cohort at Sinai
RECRUITING
-
Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases
ACTIVE NOT RECRUITING · Phase 3
-
Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency
ACTIVE NOT RECRUITING · Phase 3
-
COVID-19 Vaccine Responses in PIDD Subjects
ACTIVE NOT RECRUITING
-
Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.